GlassScriptPhysician profile
Leigh A Bennett
NPI 1275596678
$2,686.86
in general payments reported to CMS, 2019-2025
27 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $560 · 2021: $222 · 2022: $178 · 2023: $324 · 2024: $174 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.29 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $368.54 | 2019-2022 | |
| Alkermes, INC. | $211.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $206.12 | 2019-2020 | |
| Lundbeck LLC | $202.59 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $186.01 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $117.51 | 2019-2020 | |
| Bausch Health US, LLC | $115.20 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $105.23 | 2019-2020 | |
| Brainsway USA INC | $96.88 | 2023-2024 | Brainsway Deep Tms, Brainsway Deep Tms System |
| Axsome Therapeutics, INC. | $87.93 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $43.32 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $42.57 | 2019 | |
| Jazz Pharmaceuticals INC. | $34.61 | 2020-2021 | |
| Allergan, INC. | $34.49 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $33.11 | 2019-2020 | |
| Shire North American Group INC | $30.36 | 2019 | |
| Corium, LLC | $21.05 | 2022 | |
| Tris Pharma INC | $20.72 | 2020 | |
| Vanda Pharmaceuticals INC. | $19.25 | 2019 | |
| Sage Therapeutics, LLC | $18.11 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.92 | 2019 | |
| Eisai INC. | $14.22 | 2020 | |
| Neuronetics, INC. | $13.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.25 | 2021 | |
| Adlon Therapeutics L.P. | $13.06 | 2020 | |
| Lilly USA, LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.